Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820518 | 0.86 | ACACB (0.40) | PPARGPPARAKMT2AACACBFABP5 | |
| SCHEMBL16128286 | 0.85 | FABP5 (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29392800 | 0.85 | FABP5 (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL16128284 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29823789 | 0.80 | KMT2A (0.43) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL16080167 | 0.79 | PTPN1 (0.49) | PTPN1 | |
| SCHEMBL16075059 | 0.79 | PTPN1 (0.49) | PTPN1 | |
| SCHEMBL29743094 | 0.78 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL16482875 | 0.78 | ITGB3 (0.39) | PPARGPPARAKMT2AACACBFABP5 | |
| SCHEMBL117946 | 0.77 | MDM4 (0.51) | PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | HANMI FINE CHEMICAL CO., LTD. (KR) | 2026-05-05 | — | — | US | disclosed |
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | HANMI FINE CHEMICAL CO., LTD. (KR) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | VIP, IAPP, ANPEP | PPARG 4197/4885PPARA 3677/4885KMT2A 4831/4885 |
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | VIP, PTMS, HM13 | PPARG 2609/4885PPARA 3672/4885KMT2A 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.